BERGEM·HEALTH
Home Doctors Prof. Dr. Mutlu Arat
HAEMATOLOGY AND HAEMATOPOIETIC STEM CELL TRANSPLANTATION · MEMORIAL GÖZTEPE

Prof. Dr. Mutlu Arat

Professor of Haematology · Memorial Göztepe Hospital
Mutlu Arat graduated from Hacettepe University Faculty of Medicine in 1991, trained in internal medicine and then in haematology at Ankara University Faculty of Medicine, and spent 1996–1997 at the bone marrow transplant unit of Donauspital, University of Vienna, as an Austrian government scholar. He was associate professor of haematology at Ankara University from 2004 to 2009 and was a visiting professor at the University of Minnesota bone marrow transplant unit in 2008. From 2010 he founded and directed the adult haematopoietic stem cell transplantation unit at Şişli Florence Nightingale Hospital, and he has practised at Memorial Şişli since 2024 and Memorial Göztepe since 2025. He served as General Secretary of the Turkish Society of Haematology (2004–2010), chaired its stem cell transplantation scientific committee (2013–2018), and has been a JACIE inspector and a secretary of the EBMT Leukaemia Working Party (2006–2012).
Specialties: Organ Transplantation
308
indexed works (OpenAlex)
6,855
citations (OpenAlex)
39
h-index (OpenAlex)
0000-0003-2039-8557
ORCID
Allogeneic haematopoietic stem cell transplantation, including alternative-donor transplantsAutologous stem cell transplantation and high-dose chemotherapyAcute leukaemiasMultiple myelomaLymphomasMyelodysplastic syndromes and acquired aplastic anaemia
A BergemHealth coordinator arranges contact with the professor within 24–48 hours on business days.
Direct contract with BergemHealth
CONSULTATION LANGUAGES
Turkish
English
German
ISTANBUL · 08/2026
EDUCATION & CAREER

Timeline

1991–1996
Hacettepe University Faculty of Medicine, Ankara — MD
1996–1997
Bone marrow transplant unit, Donauspital, University of Vienna
1997–1999
Internal medicine, Ankara University Faculty of Medicine
1999–2001
Haematology fellowship, Ankara University Faculty of Medicine
2001–2004
Haematologist, Ankara University Faculty of Medicine
2004–2009
Associate Professor of Haematology, Ankara University Faculty of Medicine
2008
Visiting professor, bone marrow transplant unit, University of Minnesota, USA
2010–2013
Professor and Director, Department of Internal Medicine / Haematology, İstanbul Bilim University Faculty of Medicine
2010–2024
Founding Director, adult haematopoietic stem cell transplantation unit, Şişli Florence Nightingale Hospital
2024–present
Memorial Şişli Hospital, Haematology and Bone Marrow Transplantation Centre
2025–present
Memorial Göztepe Hospital, Istanbul
PUBLICATIONS

Scientific work

  • 2019
    The Lancet
    «Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study»
  • 2021
    The Lancet
    «Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial»
  • 2020
    The Lancet Haematology
    «Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation»
  • 2016
    Bone Marrow Transplantation
    «Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation»
  • 2011
    Nature Genetics
    «NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules»
REQUEST

Tell me about your case — I’ll read it personally.

Fill in the short form on the consultation page — diagnosis, preferred timing, attached records. We assemble a tumour board for your case and reply within 4 hours.

Open the consultation form
  • Reply within 4 hours during business hours
  • Confidentiality guaranteed
  • Coordinator-translator inside the doctor’s office
  • Tumour board of 2–3 professors within 72 hours